BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mentor Capital Signs $6 Million Nanotechnology Cancer LOI


11/20/2012 7:35:34 AM

SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (OTC Markets: MNTR) announced it has executed a Letter of Intent with Nanovega, Inc. for $6 million to fund the production scale up of its ultra-small synthetic antibodies. These nano-scale molecules are approximately one-tenth the size of most alternative cancer delivery bio-markers. The small size allows the nano-bodies to slip throughout solid tumors instead of piling up at the surface as is often currently encountered in cancer treatment.

Marek Malecki, MD, PhD, President of Nanovega, Inc., looks ahead, “We are enthusiastic about the financial support provided by Mentor Capital. With intellectual property protected [9 patents and applications] we look to scale up production of our unique synthetic antibodies.” The nano-bodies are already produced for use by outside researchers and designed for multiple diagnostic and therapeutic applications.

Mentor Capital CEO, Chester Billingsley, adds, “We are especially intrigued by Nanovega’s ability to tag cancer cells or fragments circulating in the blood with ultra-small metal atoms.” The metal nano-tags allow the cancer cells to be separated out using a magnetic field. The separated cancer cells may then be quickly grown and tested outside the body to predetermine the most effective chemotherapy to prescribe.

About Mentor Capital: By acquisition or stock purchase, Mentor Capital, Inc. seeks to invest in leading companies that reduce the cost of medical treatments, especially in the fight against cancer. Additional important information is presented at: www.MentorCapital.com

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

Contacts

Mentor Capital, Inc.

Chester Billingsley, CEO

(760) 788-4700



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES